1-19 of 19
Joseph E. Maakaron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

John Sharp, Paolo Strati, Subodh Bhatta, Jennifer J. Huang, Colin Thomas, Daniel K Reef, Alexander Gorzewski, Catherine Reinert, Andinet Teferra, Ari Pelcovits, Thomas Ollila, Joseph E. Maakaron, Manali K. Kamdar, Lindsey Fitzgerald, Reem Karmali, Natalie Grover, Stefan K. Barta, Timothy Voorhees, Mazyar Shadman, Sairah Ahmed, Narendranath Epperla
Journal: Blood
Blood (2024) 144 (Supplement 1): 2377.
https://doi.org/10.1182/blood-2024-203753
Published: 2024
Journal Articles

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Mohamed Sorror, Wael Saber, Brent R. Logan, Nancy Geller, Anna Bellach, Jianqun Kou, William A. Wood, John M. McCarty, Thomas G. Knight, Lyndsey Runaas, Laura Johnston, Jeremy Walston, Ryotaro Nakamura, Asmita Mishra, Joseph Uberti, Parastoo B Dahi, Jennifer N. Saultz, Shannon R McCurdy, Lawrence E Morris, Philip Imus, William J. Hogan, Kalyan Nadiminti, Vijaya Raj Bhatt, Rebecca Olin, Joseph E. Maakaron, Ronald Sobecks, Sarah A. Wall, Deborah Mattila, Bailey Protz, Steven M. Devine, Mary M. Horowitz, Andrew Artz
Journal: Blood
Blood (2024) 144 (Supplement 1): 685.
https://doi.org/10.1182/blood-2024-194414
Published: 2024
Journal Articles

A Phase II Study of Pembrolizumab+ BEAM before Autologous Stem Cell Transplant (ASCT) Followed By Pembrolizumab Maintenance in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

Sanjal H. Desai, Qing Cao, Marie Hu, Joseph E. Maakaron, Veronika Bachanova
Journal: Blood
Blood (2024) 144 (Supplement 1): 4434.3.
https://doi.org/10.1182/blood-2024-206187
Published: 2024
Journal Articles

Pre-Treatment Higher Eosinophil Count Is Associated with Improved Survival after Autologous CAR-T Therapy for Hematologic Malignancies

Sana Kagalwalla, Qing Cao, Marie Hu, Joseph E. Maakaron, Daniel O'Leary, Sean Tracy, Veronika Bachanova
Journal: Blood
Blood (2024) 144 (Supplement 1): 6247.
https://doi.org/10.1182/blood-2024-204198
Published: 2024
Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper
Journal: Blood
Blood (2024) 144 (Supplement 1): 2873.
https://doi.org/10.1182/blood-2024-205641
Published: 2024
Journal Articles

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Shernan G. Holtan, Kelly Walton, Najla H El Jurdi, Joseph E. Maakaron, Mark Juckett, Veronika Bachanova, Thomas Myers, Linda J. Paradiso, Todd DeFor, Qing Cao, Brian Betts
Journal: Blood
Blood (2023) 142 (Supplement 1): 4925.
https://doi.org/10.1182/blood-2023-181292
Published: 2023
Journal Articles

Simvastatin with Intrathecal Dexamethasone Reduces Neurotoxicity in Adults Receiving Chimeric Antigen Receptor (CAR) T-Cells Treatment

Nuttavut Sumransub, Cassie Seichter, Kateryna Kent, Ryan Shanley, Marie Hu, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeremy R. Allred, Veronika Bachanova, Jeffrey S Miller, Joseph E. Maakaron
Journal: Blood
Blood (2023) 142 (Supplement 1): 3493.
https://doi.org/10.1182/blood-2023-187070
Published: 2023
Journal Articles

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Amneet K Bajwa, Qiuhong Zhao, Marcus Johannes Geer, Agrima Mian, Chenyu Lin, David Frame, James Westholder, Justin Tossey, Monalisa Ghosh, Ahmed Galal, Nausheen Ahmed, Joseph E. Maakaron, Nathan Denlinger, Marcos de Lima, Narendranath Epperla, Paolo F. Caimi, Timothy Voorhees
Journal: Blood
Blood (2023) 142 (Supplement 1): 4502.
https://doi.org/10.1182/blood-2023-179620
Published: 2023
Journal Articles

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Joseph E. Maakaron, Cassie Seichter, Rose Wangen, Andrea Hoeschen, Deepa Kolaseri Krishnadas, Kateryna Kent, Ryan Shanley, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeffrey S Miller
Journal: Blood
Blood (2023) 142 (Supplement 1): 4842.
https://doi.org/10.1182/blood-2023-189132
Published: 2023
Journal Articles

Hematopoietic Stem Cell Transplantation with FCR001 Can Induce Durable Red Blood Cell Chimerism in a Majority of Recipients: Results of a Phase II Trial

Joel Weinthal, Jordan Olsen, Kristi Schneider, Nancy R. Krieger, Joseph E. Maakaron
Journal: Blood
Blood (2022) 140 (Supplement 1): 12675–12676.
https://doi.org/10.1182/blood-2022-156427
Published: 2022
Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Alex Hoover, Daniel O'Leary, Qing Cao, Ashish O. Gupta, Christen L. Ebens, Joseph E. Maakaron, Brian C. Betts, Mark Juckett, Troy C. Lund, Veronika Bachanova, Margaret L. MacMillan, Jeffrey S. Miller, MD, Paul J. Orchard, John E Wagner, Gregory M. Vercellotti, Daniel J. Weisdorf, Kathryn Dusenbery, Stephanie Terezakis, Shernan G Holtan, Najla H El Jurdi
Journal: Blood
Blood (2022) 140 (Supplement 1): 282–283.
https://doi.org/10.1182/blood-2022-165782
Published: 2022
Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph E. Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul J. Shaughnessy, Armin Ghobadi, Michael R. Bishop, Ana Alfonso-Pierola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant Cohen, Richard T. Maziarz, Carlos Bachier
Journal: Blood
Blood (2022) 140 (Supplement 1): 10303–10306.
https://doi.org/10.1182/blood-2022-166432
Published: 2022
Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Michael Scordo, Jessica R. Flynn, Sean M. Devlin, Mithat Gonen, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph E. Maakaron, Richard T. Maziarz, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood
Blood (2022) 140 (Supplement 1): 1588–1591.
https://doi.org/10.1182/blood-2022-164674
Published: 2022
Journal Articles

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Caron A. Jacobson, Tilanthi Jayawardena, Lou Yu, Jason Hallman, Robert Schmittling, Erin Cuneo, Ian Belle, Gavin Sampey, Danica Cabral, Ashleigh Derrick, Josie Tueller, Koen Van Besien, Scott R. Solomon, Adam J. Olszewski, Joseph E. Maakaron, Ran Reshef, Anthony S. Stein, Abhinav Deol, Nitin Jain, Alan F. List, Bijal D. Shah
Journal: Blood
Blood (2022) 140 (Supplement 1): 4588–4589.
https://doi.org/10.1182/blood-2022-165311
Published: 2022
Journal Articles

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Shernan G Holtan, Celalettin Ustun, Andrea Hoeschen, Julianne Feola, Qing Cao, Parth Gandhi, Wes Mosher, Chi Chen, Arne Slungaard, Armin Rashidi, Erica D. Warlick, Mukta Arora, Veronika Bachanova, Fiona He, Brian C. Betts, Gregory M. Vercellotti, Claudio G. Brunstein, Najla H El Jurdi, Ashish O. Gupta, Murali Janakiram, Joseph E. Maakaron, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Margaret L. MacMillan
Journal: Blood
Blood (2021) 138 (Supplement 1): 261.
https://doi.org/10.1182/blood-2021-145008
Published: 2021
Journal Articles

Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis

Najla H El Jurdi, Daniel O'Leary, Fiona He, Todd E. DeFor, Armin Rashidi, Erica D. Warlick, Ashish O. Gupta, Joseph E. Maakaron, Mukta Arora, Murali Janakiram, Arne Slungaard, Angela R. Smith, Veronika Bachanova, Claudio G. Brunstein, Margaret L. MacMillan, Jeffrey S. Miller, Brian C. Betts, Christen L. Ebens, Heather Stefanski, Troy C Lund, Paul Orchard, Gregory M. Vercellotti, Daniel J. Weisdorf, Shernan G Holtan
Journal: Blood
Blood (2021) 138 (Supplement 1): 1811.
https://doi.org/10.1182/blood-2021-147569
Published: 2021
Journal Articles

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

Veronika Bachanova, Joseph E. Maakaron, Frank Cichocki, David H. McKenna, Qing Cao, Todd E. DeFor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Bartosz Grzywacz, Ronit Simantov, Tracey Lodie, Jeffrey S. Miller
Journal: Blood
Blood (2021) 138 (Supplement 1): 3854.
https://doi.org/10.1182/blood-2021-149989
Published: 2021
Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-141606
Published: 2020
Journal Articles

High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease

Najla El Jurdi, MD, Heba Elhusseini, MD, Todd E. DeFor, MS, Grigori Okoev, MD PhD, Aleksandr Lazaryan, MDPhDMPH, John Rogosheske, PharmD, Kristen Weiler, Veronika Bachanova, MD PhD, Brian C. Betts, MD, Bruce R. Blazar, MD, Claudio G. Brunstein, MD PhD, Fiona He, MD, Shernan G Holtan, MD, Murali Janakiram, MD, Radhika Gangaraju, MD, Joseph E. Maakaron, MD, Margaret L. MacMillan, MD, Armin Rashidi, MD PhD, Erica D. Warlick, MD, Smita Bhatia, MDMPH, Joan D. Beckman, MDPhD, Gregory M Vercellotti, MD, Daniel J. Weisdorf, MD, Mukta Arora, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–46.
https://doi.org/10.1182/blood-2020-136337
Published: 2020